We've discovered 1 warning sign about Alnylam Pharmaceuticals. View them for free. Revenue exceeded analyst estimates by 1.6%. Earnings per share (EPS) also surpassed analyst estimates by 56%. Looking ...

Alnylam Pharmaceuticals Inc (ALNY) reports strong financial performance with significant growth in TTR franchise and ...

Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 20 years ago, it would be worth $3,333.42 today based on a ...

Alnylam analysts highlight Amvuttra's strong launch positioning and limited tariff risk, with bullish ratings maintained ...

Christine Lindenboom; Chief Corporate Communications Officer; Alnylam Pharmaceuticals. Yvonne Greenstreet; Chief Executive Officer, Director; Alnylam Pharmaceuticals ...

ALNY reports better-than-expected first-quarter results as both earnings and revenues beat estimates, driven by higher product sales.

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $57.5 million in its first quarter. The Cambridge, Massachusetts-based company said ...

--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (ALNY) (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March ...

Alnylam Pharmaceuticals said its RNAi therapeutic vutrisiran received a positive opinion recommending approval from the Committee for Medicinal Products for Human Use of the European Medicines Agency.

Discover Alnylam Pharmaceuticals' robust Q1 2025 earnings, highlighted by a 28% revenue growth and the successful launch of AMVUTTRA for ...

With attention focused on their recently approved drugs for transthyretin amyloid cardiomyopathy (ATTR-CM), there was a ...